Hirman, Joe

Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial

Boxer, A. L., Lang, A. E., Grossman, M., Knopman, D. S., Miller, B. L., Schneider, L. S., Doody, R. S., Lees, A., Golbe, L. I., Williams, D. R., et al. (2014) · The Lancet Neurology

Parkinson's Disease Mechanisms and TreatmentsAlzheimer's disease research and treatments

Cited by 294

Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial

Ständer, S., Kwon, P., Hirman, J., Perlman, A. J., Weisshaar, E., Metz, M., & Luger, T. A. (2019) · Journal of the American Academy of Dermatology

Dermatology and Skin DiseasesUrticaria and Related Conditions

Cited by 118

A Double-Blind, Placebo-Controlled, Ascending-Dose, Randomized Study to Evaluate the Safety, Tolerability and Effects on Cognition of AL-108 after 12 Weeks of Intranasal Administration in Subjects with Mild Cognitive Impairment

Morimoto, B. H., Schmechel, D., Hirman, J., Blackwell, A., Keith, J., Gold, M., & on behalf of the AL-108-211 Study Investigators (2013) · Dementia and Geriatric Cognitive Disorders

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 115

Safety and efficacy of a novel ANGPTL4 inhibitory antibody for lipid lowering: results from phase 1 and phase 1b/2a clinical studies

Cummings, B. B., Joing, M. P., Bouchard, P. R., Milton, M. N., Moesta, P. F., Ramanan, V., Lane, A., Hirman, J., Trauger, J. W., Maratos-Flier, E., et al. (2025) · The Lancet

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 49